ReWalk Robotics

LFWD

Market cap $10.8M

LFWD secures CE mark for its ReWalk 7 Personal Exoskeleton, unlocking new European sales potential with advanced features.

Medicare Advantage claim processed in less than thirty days Additional progress with traditional Medicare claim approvals has accelerated timelines to payment in 2025 MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, Sept.

Seventh generation of industry-leading ReWalk Exoskeleton is now cleared for commercial launch in the European Union Seventh generation of industry-leading ReWalk Exoskeleton is now cleared for commercial launch in the European Union

Lifeward Ltd. (NASDAQ:LFWD ) Q2 2025 Earnings Conference Call August 14, 2025 8:30 AM ET Company Participants Almog Adar - Chief Financial Officer William Mark Grant - President, CEO & Director Conference Call Participants Benjamin Charles Haynor - Lake Street Capital Markets, LLC, Research Division I-Eh Jen - Laidlaw & Company (UK) Ltd.

Lifeward (LFWD) came out with a quarterly loss of $0.58 per share versus the Zacks Consensus Estimate of a loss of $0.25. This compares to a loss of $0.5 per share a year ago.

Achieves r ecord n umber of ReWalk s ystems p laced f or Medicare b eneficiaries s ince fee schedule established Third consecutive quarter of U.S. ReWalk pipeline growth with over 130 qualified leads in process A ppoints n ew CEO and CFO to s pearhead s trategic c hange and a ccelerate g rowth MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, Aug. 14, 2025 (GLOBE NEWSWIRE) --  Lifeward Ltd.

MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, today announced that Almog Adar, who previously served as the Company's Vice President of Finance and Chief Accounting Officer, has been appointed as the Company's new Chief Financial Officer.

MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, today announced that the Company will release its second quarter 2025 financial results before the markets open on Thursday, August 14, 2025.

MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd.

Industry veteran with proven track record in neurorehabilitation and fundraising to lead next phase of growth; Co-founder Brian Harris transitions to Chief Scientific Officer PORTLAND, Maine , July 7, 2025 /PRNewswire/ -- MedRhythms, Inc., a company pioneering the development of next-generation neurotherapeutics to improve walking, mobility and related functional outcomes, and creator of the world's first prescription music platform, announced the appointment of Larry Jasinski as Chief Executive Officer, effective immediately. Co-founder of MedRhythms, Brian Harris, who led the company through product development, successful clinical trials, listing product with the Food and Drug Administration (FDA), and assignment by the Centers for Medicare and Medicaid Services (CMS) of a benefit category and unique Health Care Common Procedure Coding System (HCPCPS) code, will transition to the role of Chief Scientific Officer (CSO) and work with Larry to build the market and grow the company in its next phase.